Ratings by Ladenburg Thalmann (Kevin DeGeeter)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 1/30/2026 | Traws Pharma Inc. | TRAW | New Coverage | Buy (N/A) |
2.10 (1.60) |
-23.81% | Details | |
| 1/23/2026 | Decoy Therapeutics Inc. | DCOY | New Coverage | Buy (N/A) |
0.75 (0.63) |
-16% | Details | |
| 11/7/2025 | NextCure Inc. | NXTC | Upgrade | Buy (Neutral) |
9.82 (12.39) |
26.17% | Details | |
| 10/31/2025 | NovoCure Ltd. | NVCR | Maintain | Buy (N/A) |
|
Details | ||
| 7/8/2025 | ORIC Pharmaceuticals | ORIC | New Coverage | Buy (N/A) |
10.65 (13.71) |
28.73% | Details | |
| 7/8/2025 | Opko Health | OPK | New Coverage | Buy (N/A) |
1.34 (1.18) |
-11.94% | Details | |
| 7/8/2025 | NovoCure Ltd. | NVCR | New Coverage | Buy (N/A) |
16.89 (13.04) |
-22.79% | Details | |
| 7/8/2025 | NextCure Inc. | nxtc | New Coverage | Neutral (N/A) |
0.44 (9.82) |
2131.82% | Details | |
| 7/8/2025 | Cardiff Oncology | CRDF | New Coverage | Buy (N/A) |
3.65 (1.88) |
-48.49% | Details | |
| 7/20/2022 | Invitae Corporation | NVTA | Downgrade | (Buy) |
2.21 (0.02) |
-99.1% | Details | |
| 2/18/2021 | Invitae Corporation | NVTA | Upgrade | Buy (Neutral) |
47.86 (0.02) |
-99.96% | Details | |
| 8/5/2020 | Invitae Corporation | NVTA | Maintain | Buy (N/A) |
|
Details | ||
| 6/23/2020 | Invitae Corporation | NVTA | Maintain | Buy (N/A) |
|
Details | ||
| 5/13/2020 | Cyclacel Pharmaceuticals | CYCC | Maintain | Buy (N/A) |
|
Details | ||
| 5/6/2020 | Invitae Corporation | NVTA | Maintain | Buy (N/A) |
|
Details | ||
| 8/7/2019 | Invitae Corporation | NVTA | Maintain | Buy (N/A) |
|
Details | ||
| 7/12/2019 | Invitae Corporation | NVTA | Maintain | Buy (N/A) |
|
Details | ||
| 10/1/2018 | Neon Therapeutics | NTGN | New Coverage | Buy (N/A) |
8.40 (3.07) |
-63.45% | Details | |
| 9/20/2018 | Invitae Corporation | NVTA | Maintain | Buy (N/A) |
|
Details | ||
| 9/7/2018 | Cyclacel Pharmaceuticals | CYCC | New Coverage | Buy (N/A) |
1.48 (6.37) |
330.41% | Details | |
| 9/5/2018 | Vericel Corporation | VCEL | Maintain | Buy (N/A) |
|
Details |
